92.9 F
San Fernando
Monday, Nov 4, 2024

Arcutis Biotherapeutics Obtains $225 Million in Debt Financing

Arcutis Biotherapeutics has secured a $225 million term loan facility from funds managed by SLR Capital Partners.

The additional capital will act as a boon to the Arcutis’ balance sheet as it prepares for a potential Food and Drug Administration approval and launch of its topical roflumilast cream for plaque psoriasis.

According to a statement from Arcutis, the financing will also extend the cash runway of the Westlake Village company into 2024.

“SLR is excited to be a long-term partner with Arcutis as they advance topical roflumilast in a number of pivotal Phase 3 development programs and prepare for a commercial launch,” Anthony Storino, SLR’s head of life science finance, said in a statement.

Pursuant the terms of the loan facility, $75 million was drawn at closing. $125 million will become available upon FDA approval of Arcutis’ roflumilast cream and an additional $25 million could be made available if certain revenue milestones are achieved. January 2027 is the loan facility maturity date, with the interest-only period extending for the full five years.

“This additional financing further strengthens our balance sheet at an attractive cost of capital and provides us with enhanced financial flexibility as we prepare for the potential launch of roflumilast cream in 2022, while simultaneously advancing our product candidates through multiple late-stage clinical trials, furthering our mission of bringing innovative treatments to dermatologists and millions of patients with serious skin diseases,” Frank Watanabe, Arcutis’ chief executive, said in a statement.

Shares of Arcutis closed up 72 cents, or nearly 3.6 percent, to $20.94 on the Nasdaq Tuesday, a day when the market closed down a fraction of a percent.

Antonio Pequeño IV
Antonio Pequeño IV
Antonio “Tony” Pequeño IV is a reporter covering health care, finance and law for the San Fernando Valley Business Journal. He specializes in reporting on some of the biggest names in the Valley’s biotechnology sector. In addition to his work with the Business Journal, Tony has reported with BuzzFeed News on the unsupervised use of Clearview AI, a controversial facial recognition technology. Tony, who also conducts freelance reporting, graduated from the USC’s Master of Science in Journalism program in 2021. He is in his fifth year as a journalist as of 2021.

Featured Articles

Related Articles